Publication

Video

Supplements and Featured Publications

Therapeutic Changes in HER2+ Breast Cancer
Volume1
Issue 1

Novel Treatments in HER2-Positive Breast Cancer

OncLive interviewed experts on novel treatments in HER2-positive breast cancer. 

OncLive interviewed experts on novel treatments in HER2-positive breast cancer.

Supported by an unrestricted educational grant by Daiichi Sankyo

Articles in this issue
Novel Treatments in HER2-Positive Breast Cancer
Novel Treatments in HER2-Positive Breast Cancer
Dr. Thompson on Sequencing Strategies in HER2+ Breast Cancer
Dr. Thompson on Sequencing Strategies in HER2+ Breast Cancer
Dr. Hurvitz on Treatment Options in Early-Stage HER2+ Breast Cancer
Dr. Hurvitz on Treatment Options in Early-Stage HER2+ Breast Cancer
Dr. Olajide on Managing Risk of Interstitial Lung Disease With Trastuzumab Deruxtecan in Breast Cancer
Dr. Olajide on Managing Risk of Interstitial Lung Disease With Trastuzumab Deruxtecan in Breast Cancer
Dr. Krill-Jackson on the Potential Utility of Trastuzumab Deruxtecan in Metastatic Breast Cancer
Dr. Hurvitz on Additional Research Needed With Trastuzumab Deruxtecan in HER2+ Breast Cancer
Dr. Hurvitz on Additional Research Needed With Trastuzumab Deruxtecan in HER2+ Breast Cancer
Related Videos
Related Content
NCCN: Image by Kellie Ehrmann/MJH Life Sciences using AI
December 31st 2024

Critical Recent NCCN Guideline Updates Affect Dozens of Malignancies

Alexey Danilov, MD, PhD, Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, medical director, Early Phase Therapeutics Program, the Systems Clinical Trials Office, co-director, Toni Stephenson Lymphoma Center, professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope; Susan M. O'Brien, MD, associate director, Clinical Science, Chao Family Comprehensive Cancer Center, medical director, Sue & Ralph Stern Center for Clinical Trials & Research, professor, medicine, Division of Hematology/Oncology, University of California Irvine School of Medicine
December 31st 2024

Explore the Evolving Role of BTK Inhibitors in CLL: With Alexey Danilov, MD, PhD; and Susan M. O'Brien, MD

OncLive’s December Roundup of Key FDA Approvals in Oncology
December 30th 2024

OncLive’s December Roundup of Key FDA Approvals in Oncology

James J. Harding, MD, director, Early Drug Development, Memorial Sloan Kettering Cancer Center
December 30th 2024

FDA Approval Insights: Zanidatamab in Pretreated, HER2+ Biliary Tract Cancer

Non–Small Cell Lung Cancer | Image Credit: © Katsyarina – stock.adobe.com
December 30th 2024

T-DXd Plus Pembrolizumab Elicits Responses in IO-Naive HER2-Expressing or -Mutant NSCLC

Rafael Fonseca, MD
December 30th 2024

Working on the Frontlines of a Revolution in Multiple Myeloma Care